MDGN201 TARGTEPO
MG-EP-RF-04
Phase 2 mab terminated
Quick answer
MDGN201 TARGTEPO for Anemia of End Stage Renal Disease is a Phase 2 program (mab) at Avalo Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Avalo Therapeutics
- Indication
- Anemia of End Stage Renal Disease
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated